Management of Anticoagulation in Patients with Breast Hematoma

Initial Assessment and Valve Type Determination

The American Heart Association recommends verifying valve type immediately to determine the management strategy, as mechanical valves have a contraindication with Eliquis (apixaban) due to excessive thrombotic complications and bleeding events 1
For patients with mechanical heart valves, the American College of Cardiology advises against the use of direct oral anticoagulants like apixaban, citing a 5% stroke rate compared to 0% with warfarin, and increased bleeding events 1

The American Stroke Association suggests that for bioprosthetic valves, apixaban should not be stopped immediately for a non-life-threatening soft tissue hematoma, as the risk of thromboembolic events outweighs the risk of bleeding 3, 4
The European Society of Cardiology recommends applying local compression, ice, and supportive measures to manage the hematoma, and evaluating hematoma expansion through serial physical examinations over 24-48 hours 3, 4

The American College of Chest Physicians advises that andexanet alfa is the preferred reversal agent for apixaban in cases of life-threatening bleeding, achieving a 93% reduction in anti-Xa activity within minutes 3
The International Society on Thrombosis and Haemostasis recommends resuming apixaban as soon as adequate hemostasis is established, without waiting for a specific time interval, to minimize the risk of thromboembolic events 5, 6

The American College of Cardiology recommends standard apixaban dosing of 5 mg twice daily (or 2.5 mg twice daily if ≥2 of: age ≥80, weight ≤60kg, creatinine ≥1.5 mg/dL) for bioprosthetic valves with atrial fibrillation 9
The European Society of Cardiology suggests avoiding the addition of antiplatelet therapy unless there is a specific coronary indication, as this increases bleeding risk without reducing stroke risk 9